Robuta

https://www.seameocongress.org/ Wee1 inhibitor Identified Using Pharmacological Interactions – Wee1 inhibitors wee1inhibitoridentifiedusingpharmacological https://www.rcsb.org/structure/5VC5 RCSB PDB - 5VC5: Crystal structure of human WEE1 kinase domain in complex with PD-166285 Crystal structure of human WEE1 kinase domain in complex with PD-166285 https://www.jci.org/articles/view/161544/citations JCI - Citations to ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial... https://www.prnewswire.co.uk/news-releases/debiopharm-further-explores-the-potential-of-its-potent-highly-selective-wee1-inhibitor-debio-0123-in-phase-1-cancer-study-898649089.html Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123... /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched... https://pmc.ncbi.nlm.nih.gov/articles/PMC10427618/ Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype... Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We... https://www.semanticscholar.org/topic/WEE1-protein%2C-human/3427638 WEE1 protein, human | Semantic Scholar Wee1-like protein kinase (646 aa, ~72 kDa) is encoded by the human WEE1 gene. This protein plays a role in cell cycle progression and protein phosphorylation. wee1proteinhumansemanticscholar https://zentalis.com/ Zentalis Pharmaceuticals | Advancing WEE1-Targeted Oncology May 7, 2026 - Zentalis Pharmaceuticals is a clinical-stage company advancing azenosertib, a first-in-class WEE1 inhibitor, for ovarian cancer and other tumor types. pharmaceuticalsadvancingwee1targetedoncology https://www.jci.org/articles/view/161544/figure/2 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.fredhutch.org/en/news/spotlight/2019/03/crd_diab_molcanres.html Head and neck cancer cells are sensitive to WEE1 inhibition - Fred Hutch Mar 18, 2019 - Deficiency in tumor suppressor p53 might allow head and neck cancer cells to proliferate better but also makes them vulnerable to a cell cycle kinase inhibitor. head and neck cancer https://www.jci.org/articles/view/161544/figure/1 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.jci.org/articles/view/161544/usage JCI - Usage information: ODF2L acts as a synthetic lethal partner with WEE1 inhibition in... https://www.jci.org/articles/view/161544/figure/3 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.wikidata.org/wiki/Q34000451 mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. - Wikidata in the https://www.jci.org/articles/view/161544/figure/4 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.jci.org/articles/view/161544/figure/5 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.preprints.org/manuscript/202106.0158 Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 Mutations[v1] |... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1271847/full Frontiers | Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma Multiple myeloma (MM) is a hematological malignancy characterized by an abnormal clonal proliferation of malignant plasma cells. Despite the introduction of ... https://www.jci.org/articles/view/122622/pdf JCI - Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses... https://www.jci.org/articles/view/161544/sd/4 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.salon.com/topic/wee1-tactical Wee1 Tactical Archives - Salon.com archives salonwee1tactical https://www.jci.org/articles/view/161544/figure/7 JCI - ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer... https://www.biospace.com/impact-therapeutics-announced-first-patient-dose-of-wee1-inhibitor-imp7068-in-the-u-s Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S. - BioSpace Mar 10, 2021 - Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the...